BioSpace News Archive

Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), today announced its financial results for the quarter ended June 30, 2022, and provided an overview of recent business highlights.

Illumina, Inc. announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

Poseida Therapeutics, Inc. announced business updates and financial results for the second quarter ended June 30, 2022.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended June 30, 2022.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2022 to all shareholders of record as of September 15, 2022.

Viveve Medical, Inc., a medical technology company focused on women’s health and the treatment of stress urinary incontinence, reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call.

Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the second quarter ended June 30, 2022.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, reported financial results and business highlights for the second quarter ended June 30, 2022.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.